State Biosimilar Bills Pose New Threat To Budding Industry

Spurred by safety concerns from brand-name drugmakers, state legislators around the country are proposing to restrict patient access to generic versions of pricey biologic medicines, posing a threat to the fledgling...

Already a subscriber? Click here to view full article